Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6036797 | 0.84 | CDK1 (0.34) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL11801311 | 0.82 | ADORA2A (0.31) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL6009519 | 0.80 | ADORA2A (0.38) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL13269040 | 0.79 | TLR8 (0.34) | — | |
| SCHEMBL13268707 | 0.79 | TLR8 (0.34) | — | |
| SCHEMBL4364337 | 0.78 | CDK1 (0.36) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL6267281 | 0.78 | USP2 (0.30) | — | |
| SCHEMBL16103450 | 0.76 | QPCT (0.35) | — | |
| SCHEMBL7165315 | 0.75 | CDK1 (0.31) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL669639 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1996 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013071079-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-16 | — | — | WO | claimed |
| WO-2026106956-A1 | DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-21 | — | — | US | disclosed |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | MODERNATX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2026102123-A1 | SEQUENCE CAPTURE TECHNOLOGY AND PROBE DESIGN | MONSANTO TECHNOLOGY LLC (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026098737-A1 | NUCLEIC ACID CONJUGATE AND PHARMACEUTICAL COMPOSITION FOR LIPID DELIVERY, AND USE THEREOF | 苏州时安生物技术有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | ADVANCED RNA VACCINE ARV TECH INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260132405-A1 | Modulation of Apolipoprotein C-III (ApoCIII) Expression in Lipoprotein Lipase Deficient (LPLD) Populations | IONIS PHARMACEUTICALS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | MODERNATX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260108595-A1 | BETACORONAVIRUS mRNA VACCINES | MODERNATX, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20050221275-A1 | Hepatocyte free uptake assays | ISIS PHARMACEUTICALS, INC. | 2005-10-06 | — | — | US | disclosed |
| EP-1560840-A2 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | Isis Pharmaceuticals, Inc. (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20050164209-A1 | Hepatocyte free uptake assays | ISIS PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |
| US-20050080246-A1 | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation | IONIS PHARMACEUTICALS, INC. | 2005-04-14 | — | — | US | disclosed |
| WO-2005013901-A2 | OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20050026160-A1 | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation | IONIS PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2004044136-A2 | COMPOSITIONS COMPRISING ALTERNATING 2’-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2003008550-A2 | SYNTHESIS OF OLIGONUCLEOTIDES ON SOLID SUPPORTS INCLUDING NON-REACTIVE SOLID DILUENTS | ISIS PHARMACEUTICALS, INC. (US) | 2003-01-30 | — | — | WO | disclosed |
| EP-1137658-A1 | METHODS OF MODULATING TUMOR NECROSIS FACTOR $g(a)-INDUCED EXPRESSION OF CELL ADHESION MOLECULES | ISIS PHARMACEUTICALS, INC. (US) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000034303-A1 | METHODS OF MODULATING TUMOR NECROSIS FACTOR α-INDUCED EXPRESSION OF CELL ADHESION MOLECULES | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080246-A1 | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation | NSUN2, RNMT, NSUN3 | CDK1 3493/4885CCNB1 2772/4885CCNA2 899/4885 |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | RNGTT, CDA, DCTD | CDK1 1534/4885CCNB1 790/4885CCNA2 768/4885 |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | RNMT, RNGTT, METTL16 | CDK1 4464/4885CCNB1 3763/4885CCNA2 3037/4885 |
| US-20260108595-A1 | BETACORONAVIRUS mRNA VACCINES | RNMT, METTL16, NSUN2 | CDK1 4626/4885CCNB1 3460/4885CCNA2 3719/4885 |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | NSUN2, RNMT, RNGTT | CDK1 3011/4885CCNB1 1626/4885CCNA2 1994/4885 |
| US-20050026160-A1 | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation | NSUN2, RNMT, NSUN3 | CDK1 3493/4885CCNB1 2772/4885CCNA2 899/4885 |
| US-20260132405-A1 | Modulation of Apolipoprotein C-III (ApoCIII) Expression in Lipoprotein Lipase Deficient (LPLD) Populations | LPL, APOL1, PNLIP | CDK1 4503/4885CCNB1 3894/4885CCNA2 4647/4885 |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | UPF1, NSUN2, CD4 | CDK1 3896/4885CCNB1 3735/4885CCNA2 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.